Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study
Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Nesina Leads Similar Diabetes Drugs in Adverse Events: Report April 17, 2014 Irvin Jackson Add Your Comments A new report that examines the potential the side effects and adverse events reported in connection with certain newer diabetes drugs finds that the DPP-4 inhibitor Nesina may be of significant concern, and also appears to support claims that all incretin mimetics increase the risks of pancreatitis and pancreatic cancer. The drug safety report was published this month by AdverseEvents.com, looking at data from the FDA’s Adverse Event Reporting System (FAERS). The event reports are sent in by doctors, patients and the drug companies themselves and detail adverse incidents linked to the drugs’ use. The AdverseEvents.com study looks at three fairly new classes of diabetes drugs, including sodium-glucose co-transporter 2 (SGLT2) inhibitors, known as glucuretics; as well as glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, both of which are known as incretin mimetics. These drugs are often prescribed to type 2 diabetics who are unable to control their glucose levels with diet, exercise and so-called first-line diabetic drugs like metformin. Learn More About Byetta Lawsuit Side effects of Byetta, Victoza, Januvia and other diabetes drugs may increase risk of pancreatic cancer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Byetta Lawsuit Side effects of Byetta, Victoza, Januvia and other diabetes drugs may increase risk of pancreatic cancer. Learn More SEE IF YOU QUALIFY FOR COMPENSATION The study found that, as a group, GLP-1 agonists, which include Byetta, Bydureon and Victoza were linked to the highest overall rates of hospitalization, death and other problems. However, within that number, Bydureon was the best tolerated of all the diabetes drugs, even those from other classes. Nesina (alogliptin), a DPP-4 incretin mimetic had the highest percentage of adverse event reports that resulted in life-threatening complications or hospitalization, and also had a high percentage of cases that resulted in death. However, the study’s authors note that the overall numbers for Nesina were low when you looked at actual numbers and not percentages, and they expressed less confidence in their findings because of the low total numbers. The study also looked at pancreatic cancer concerns with incretin mimetic diabetes drugs, finding that the adverse event reports support recent claims that the medications pose an carry risk of pancreatitis and pancreatic cancer, despite some reports which say there is no increased risk. AdverseEvents.com found that DPP-4 inhibitors, which include Janumet, Januvia and Nesina, had “high disproportionality results for both pancreatitis and pancreatic cancer.” “Within the class, Janumet and Januvia (both containing sitagliptin) had the highest associations with these side effects,” the report concludes. “Somewhat surprisingly the DPP-4’s had higher percentages of their case reports as “hospitalization” and “death,” when compared to the GLP-1’s. Nesina showed the highest signals of any DPP-4’s for hepatic, gallbladder, and cancer categories.” Pancreatic Cancer Concerns A number of other studies have suggested a strong association between the diabetes drugs and pancreatic cancer and pancreatitis, though none demonstrate a cause and effect relationship, which is traditionally hard to find in such cases. The most recent study was published in October by Italian researchers, who looked at 1,169 adverse drug reaction reports. They identified at least 90 cases of users of incretin mimetics suffering from pancreatitis and elevated pancreatic enzymes. Acute or chronic pancreatitis can lead to the development of pancreatic cancer in some cases. In February 2013, researchers from Johns Hopkins in Baltimore found that taking Januvia or Byetta may double the risk of hospitalization due to pancreatitis, which raised concerns about whether this may also suggest an increased risk of pancreatic cancer. In March 2013, the risk of pancreatic cancer from Januvia, Byetta and other incretin mimetics gained additional attention after another study published in the medical journal Diabetes found that pancreas tissue from organ donors found that those who took an incretin mimetic were more likely to have increased pancreatic mass and precancerous cells, which are cells with the potential to evolve into tumors. However, in February 2014, the FDA and the European Medicines Agency (EMA) published data in the New England Journal of Medicine suggesting that there was no link between the drugs and pancreatic cancer risk. Incretin Mimetics Litigation Amid the increase concerns about the risk of pancreatic cancer, a growing number of Byetta lawsuits, Januvia lawsuits, Janumet lawsuits and Victoza lawsuits have been filed by individuals throughout the country who allege that the drug makers failed to adequately research the medicatons or warn about the potential risk. Byetta, Januvia, Janumet and Victoza are all part of the incretin mimetic class of diabetes drugs, which work by mimicking the incretin hormones the body usually produces to naturally stimulate the release of insulin in response to a meal. Byetta (exenatide) was the first member of the incretin mimetic class approved by the FDA, introduced by Amylin Pharmaceuticals in 2005 as a twice daily injection. Victoza (liraglutide) is a similar injectable diabetes drug introduced by Novo Nordisk in 2010 as a longer-acting daily injection. Januvia (sitagliptin) was introduced by Merck as an oral incretin mimetic diabetes drug in 2006, and has become one of the most widely used members of the class. A combination pill containing Januvia and the older diabetes medication metformin was introduced in 2007 under the brand name Janumet. In August 2013, the U.S. Judicial Panel on Multidistrict Litigation established consolidated proceedings in the federal court system for cases filed by individuals who allege the makers of the Byetta, Januvia, Janumet and Victoza failed to adequately warn consumers and the medical community about the risk of pancreatic cancer. There are currently more than 350 pancreatic cancer cases centralized before U.S. District Judge Anthony J. Battaglia in the Southern District of California, to reduce duplicative discovery into common issues, avoid conflicting pretrial rulings from different judges and to serve the convenience of the parties, witnesses and the courts. Tags: Byetta, Diabetes, Diabetes Drugs, Janumet, Januvia, Nesina, Pancreatic Cancer, Pancreatitis, Victoza More Byetta Lawsuit Stories Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study March 25, 2021 Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020 December 30, 2019 Januvia Pancreatic Cancer Lawsuit To Be Decided By Jury, Illinois Appeals Court Determines January 2, 2019 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermPhoneThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Ozempic Side Effects Caused Stomach Paralysis and Severe Abdominal Pain, Lawsuit Claims (Posted: 2 days ago) A product liability lawsuit filed against Novo Nordisk accuses the drug maker of failing to provide adequate warnings of Ozempic side effects, like stomach paralysis. MORE ABOUT: OZEMPIC LAWSUITOzempic Gastroparesis Lawsuit Filed Over Nausea, Severe Abdominal Pain (04/04/2025)Ozempic Delayed Gastric Emptying Led to Stomach Paralysis: Lawsuit (03/27/2025)Court Urged To Reject Motion To Dismiss Lawsuits Over Ozempic, Mounjaro Gastrointestinal Risks (03/21/2025) More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: 3 days ago) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025) Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 4 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)
Trulicity, Byetta, Victoza, Similar Diabetes Drugs Do Not Appear to Increase Breast Cancer Risks: Study March 25, 2021
Pancreatic Cancer Lawsuits Over Byetta, Victoza and Other Diabetes Drugs Won’t Be Selected For Bellwether Trials Until Late 2020 December 30, 2019
Januvia Pancreatic Cancer Lawsuit To Be Decided By Jury, Illinois Appeals Court Determines January 2, 2019
Ozempic Side Effects Caused Stomach Paralysis and Severe Abdominal Pain, Lawsuit Claims (Posted: 2 days ago) A product liability lawsuit filed against Novo Nordisk accuses the drug maker of failing to provide adequate warnings of Ozempic side effects, like stomach paralysis. MORE ABOUT: OZEMPIC LAWSUITOzempic Gastroparesis Lawsuit Filed Over Nausea, Severe Abdominal Pain (04/04/2025)Ozempic Delayed Gastric Emptying Led to Stomach Paralysis: Lawsuit (03/27/2025)Court Urged To Reject Motion To Dismiss Lawsuits Over Ozempic, Mounjaro Gastrointestinal Risks (03/21/2025)
More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: 3 days ago) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)
Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 4 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)